Dr. Michael Goldstein, MD
Endocrinology & Diabetes (Endocrinology, Diabetes & Metabolism Physician)
- Medicare participating
At a glance
- Years since graduation
- 8
- In the NPI registry since
- 2018
- Medicare patients seen, 2024
- 487
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2018Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Endocrinology, Diabetes & Metabolism Physician primary
NY license 308626
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- NYU Langone Hospitals New York, NY
Medical groups
- New York University (6,134 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 487
- Services billed
- 2,294
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 121 | 99 |
| Blood glucose (sugar) test performed by hand-held instrument | 112 | 93 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 62 | 41 |
| Hemoglobin a1c level | 42 | 40 |
| New patient office or other outpatient visit, 45-59 minutes | 27 | 27 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Ozempic (semaglutide) Other prescribers in Mineola, NY | 258 |
| Jardiance (empagliflozin) Other prescribers in Mineola, NY | 245 |
| Mounjaro (tirzepatide) Other prescribers in Mineola, NY | 173 |
| Atorvastatin Calcium Other prescribers in Mineola, NY | 148 |
| Lantus Solostar (insulin glargine,hum.rec.anlog) Other prescribers in Mineola, NY | 139 |
| Metformin Hcl Er (metformin hcl) Other prescribers in Mineola, NY | 134 |
| Levothyroxine Sodium Other prescribers in Mineola, NY | 122 |
| Rosuvastatin Calcium Other prescribers in Mineola, NY | 113 |
| Trulicity (dulaglutide) Other prescribers in Mineola, NY | 100 |
| Metformin Hcl Other prescribers in Mineola, NY | 96 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $4,500 in research payments for these studies, mostly to the institutions running them.
- A prospective, randomized, non-blinded study of the effect of continuous glucose monitoring on glycemic management in patients new-to-insulin on hospital discharge
Dexcom, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.